MarginsXMarginsX
Home › Data Desk › Nektar Therapeutics reports $34.7M of cash, about 1.6 months at its recent burn

MarginsX Data Desk · Quarterly results

Nektar Therapeutics reports $34.7M of cash, about 1.6 months at its recent burn

Nektar Therapeutics (NKTR) filed its 10-Q on Nov 13, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 13, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 13, 2026.

Line chart of Nektar Therapeutics (NKTR) daily closes from Jul 6, 2026 to Nov 12, 2026, with the results filing on Nov 13, 2026 marked.

Revenue and margins

Revenue was $9.4M, down 20.4% from $11.8M in the same period a year earlier, which ended Sep 30, 2025. (SEC XBRL company facts, 10-Q, Nov 13, 2026)

The net loss was $55.7M. (SEC XBRL company facts, 10-Q, Nov 13, 2026)

Balance sheet

Cash was $34.7M at Sep 30, 2026, against $39.3M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Shares outstanding were 34.2 million, against 34.1 million at Jun 30, 2026, a rise of 0.2%. (SEC XBRL company facts, 10-Q, Nov 13, 2026)

At its recent quarterly burn of $64.2M, that cash lasts about 1.6 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

The stock

The Nasdaq screener puts its market value at $1.3B. (Nasdaq stock screener, Nov 13, 2026)

State Street Corp passes 5.0% of Nektar Therapeutics

In a Schedule 13G filed Nov 10, 2026, State Street Corp reported 1.8 million shares of Nektar Therapeutics (NKTR) as of Sep 30, 2026, 5.2% of the class. (SEC EDGAR, SCHEDULE 13G, Nov 10, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/NKTR)

The filing on SEC EDGAR. (sec.gov)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameNektar TherapeuticsSource2026-11-13
Cash34,686,000 USDSource2026-09-30
Runway1.6 monthsSource2026-09-30
WhoNektar Therapeutics (NKTR)Source2026-11-13
SymbolNKTRSource2026-11-13
Form10-QSource2026-11-13
FiledNov 13, 2026Source2026-11-13
Period endSep 30, 2026Source2026-11-13
Revenue9,386,000 USDSource2026-11-13
Revenue change-0.204 %Source2026-11-13
Revenue a year earlier11,790,000 USDSource2026-11-13
A year earlier endSep 30, 2025Source2026-11-13
Net loss55,651,000 USDSource2026-11-13
Net income-55,651,000 USDSource2026-11-13
Cash prior39,267,000 USDSource2026-08-14
Prior endJun 30, 2026Source2026-08-14
Shares34,214,683 sharesSource2026-11-13
Shares prior34,142,994 sharesSource2026-08-14
Dilution0.002 %Source2026-11-10
Burn abs64,239,250 USDSource2026-09-30
Burn-64,239,250 USDSource2026-09-30
Cap1,271,826,527 USDSource2026-11-13
FormSchedule 13GSource2026-11-10
FiledNov 10, 2026Source2026-11-10
FilerState Street CorpSource2026-11-10
Shares1,772,302 sharesSource2026-11-10
Event dateSep 30, 2026Source2026-11-10
Pct5.2 %Source2026-11-10

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS